Tempest Therapeutics
TPST
23 hedge funds and large institutions have $1.05M invested in Tempest Therapeutics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
5% more funds holding
Funds holding: 22 → 23 (+1)
7.41% less ownership
Funds ownership: 33.02% → 25.61% (-7.4%)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
82% less capital inflows, than outflows
Capital inflows: $90.9K | Capital outflows: $515K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$33.1K |
| 2 |
HRT Financial
New York
|
+$22.1K |
| 3 |
Virtu Financial
New York
|
+$18.7K |
| 4 |
Millennium Management
New York
|
+$8.27K |
| 5 |
Two Sigma Securities
New York
|
+$5.12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$279K |
| 2 |
EcoR1 Capital
San Francisco,
California
|
-$142K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$72K |
| 4 |
Renaissance Technologies
New York
|
-$11K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$8.25K |
TPST Hedge Fund Activity: Q3 2023 in Review
23 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q3 2023, worth a combined $1.05M — down 78% from $4.86M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new TPST positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 7 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $33.1K. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $279K sold.
- 23 institutional investors held Tempest Therapeutics (TPST) as of Q3 2023, up from 22 in Q2 2023.
- Funds reported $1.05M of Tempest Therapeutics stock for Q3 2023, down 78% quarter-over-quarter.
- 4 funds opened new Tempest Therapeutics positions in Q3 2023 and 3 closed out, a net change of +1 holder.
- The largest Tempest Therapeutics buyer in Q3 2023 was Citadel Advisors, an estimated $33.1K added.
- The largest Tempest Therapeutics seller in Q3 2023 was Sectoral Asset Management, an estimated $279K sold.
Based on aggregated 13F filings for Q3 2023.